[go: up one dir, main page]

AR108442A1 - Proteínas de fusión gdf15 y usos de estas - Google Patents

Proteínas de fusión gdf15 y usos de estas

Info

Publication number
AR108442A1
AR108442A1 ARP170101236A ARP170101236A AR108442A1 AR 108442 A1 AR108442 A1 AR 108442A1 AR P170101236 A ARP170101236 A AR P170101236A AR P170101236 A ARP170101236 A AR P170101236A AR 108442 A1 AR108442 A1 AR 108442A1
Authority
AR
Argentina
Prior art keywords
region
gdf15
fusion proteins
sec
identity
Prior art date
Application number
ARP170101236A
Other languages
English (en)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR108442A1 publication Critical patent/AR108442A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se describen proteínas de fusión que contienen una proteína de extensión de la semivida, un enlazador y una proteína GDF15. Se describen, además, ácidos nucleicos que codifican las proteínas de fusión, células recombinantes de estos, composiciones que comprenden las proteínas de fusión y métodos de usar las proteínas de fusión para el tratamiento o prevención de enfermedades metabólicas, trastornos o afecciones. Reivindicación 13: Una proteína de fusión que comprende una secuencia de aminoácidos que tiene al menos 90% de identidad de secuencia con las sec. con núm. de ident.: 5, 25 - 30, 36 - 37, 40, 48, 55 - 56, 59 - 60, 64 - 75, 92, 113, 115, 117, 119, 121, 123, 125, ó 127. Reivindicación 15: Una molécula aislada de ácido nucleico que comprende una secuencia de nucleótidos que codifica la proteína de fusión de acuerdo con cualquier reivindicación 1 a 14. Reivindicación 37: Un dímero que comprende (i) una primera cadena polipeptídica que comprende una primera región de HSA en el extremo N-terminal, un enlazador y una primera región de GDF15 en el extremo C-terminal y (ii) una segunda cadena polipeptídica que comprende una segunda región de GDF15; en donde la región de HSA comprende una secuencia de aminoácidos que tiene al menos 90% de identidad con las sec. con núm. de ident.: 1, 2, ó 3 y en donde la primera región de GDF15 comprende una secuencia de aminoácidos que tiene al menos 90% de identidad con las sec. con núm. de ident.: 6, 7, 8, 9, 10, u 11 y la segunda región de GDF15 comprende una secuencia de aminoácidos que tiene al menos 90% de identidad con las sec. con núm. de ident.: 6, 7, 8, 9, 10 u 11.
ARP170101236A 2016-05-10 2017-05-10 Proteínas de fusión gdf15 y usos de estas AR108442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662333886P 2016-05-10 2016-05-10

Publications (1)

Publication Number Publication Date
AR108442A1 true AR108442A1 (es) 2018-08-22

Family

ID=60266761

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101236A AR108442A1 (es) 2016-05-10 2017-05-10 Proteínas de fusión gdf15 y usos de estas

Country Status (29)

Country Link
US (3) US10336812B2 (es)
EP (1) EP3454832A4 (es)
JP (3) JP7022879B2 (es)
KR (2) KR20230169417A (es)
CN (1) CN109451726A (es)
AR (1) AR108442A1 (es)
AU (3) AU2017263237B2 (es)
BR (1) BR112018072946A2 (es)
CA (1) CA3022865A1 (es)
CL (1) CL2018003148A1 (es)
CO (1) CO2018012096A2 (es)
CR (2) CR20230026A (es)
DO (1) DOP2018000245A (es)
EA (1) EA201892561A1 (es)
EC (1) ECSP18083561A (es)
IL (3) IL262652B2 (es)
MA (1) MA44986A (es)
MX (2) MX2018013784A (es)
MY (1) MY191030A (es)
NI (1) NI201800121A (es)
NZ (2) NZ787709A (es)
PE (2) PE20190352A1 (es)
PH (1) PH12018502361B1 (es)
SG (2) SG10201912739XA (es)
SV (1) SV2018005781A (es)
TW (3) TWI760333B (es)
UA (1) UA129532C2 (es)
WO (1) WO2017196647A1 (es)
ZA (1) ZA201808284B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
JP6509852B2 (ja) 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
EP3184106A1 (en) * 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CA3025251A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and uses thereof
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US20190224278A1 (en) * 2018-01-22 2019-07-25 Intelligent Synthetic Biology Center Producing method of antimicrobial peptide with enhanced adhesion and uses thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CA3096097A1 (en) 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
JP2022505876A (ja) * 2018-10-26 2022-01-14 フリーイェ・ユニヴェルシテイト・ブリュッセル 遺伝子治療を向上させる新しいツール及びその使用
US20220315633A1 (en) * 2018-11-20 2022-10-06 Janssen Pharmaceutica Nv Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake
BR112021016973A2 (pt) * 2019-02-27 2021-11-30 Daewoong Pharmaceutical Co Ltd Proteína de fusão, seu método de preparação e uso, molécula de ácido nucleico, vetor recombinante, transformante e composição farmacêutica
EP3932430A4 (en) * 2019-02-27 2023-02-01 Daewoong Pharmaceutical Co., Ltd. ALBUMIN-RELATED COMPOSITION COMPRISING LRRD2 OF THE SLIT3 PROTEIN FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
US20230053119A1 (en) * 2019-04-23 2023-02-16 Lg Chem, Ltd. FUSION POLYPEPTIDE COMPRISING Fc REGION OF IMMUNOGLOBULIN AND GDF15
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
AU2020394255A1 (en) * 2019-11-26 2022-06-09 Yuhan Corporation Long-acting GDF15 fusion protein and pharmaceutical composition comprising same
MY209909A (en) * 2019-12-11 2025-08-11 Lg Chemical Ltd Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
WO2021133822A1 (en) * 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN114560938B (zh) * 2020-03-30 2023-05-23 中国人民解放军第四军医大学 抗gdf15中和性单克隆抗体及其应用
CN115244076B (zh) * 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US7919084B2 (en) * 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
NZ543292A (en) * 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US20120107420A1 (en) * 2008-10-31 2012-05-03 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
TW201101990A (en) 2009-07-08 2011-01-16 zhen-zheng Huang Plant media
AU2010276453A1 (en) * 2009-07-20 2012-02-09 Dcb-Usa Llc Polypeptides selective for av beta3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CN105073133B (zh) * 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
PT2948559T (pt) * 2013-01-25 2018-07-24 Janssen Biotech Inc ¿antagonistas de kv1.3 e métodos de utilização
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6509852B2 (ja) * 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
RU2017101436A (ru) * 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US10603359B2 (en) * 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
GB201512733D0 (en) * 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
US20190234935A1 (en) * 2016-10-12 2019-08-01 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение

Also Published As

Publication number Publication date
AU2021218103A1 (en) 2021-09-09
AU2023266233A1 (en) 2023-12-07
EA201892561A1 (ru) 2019-04-30
JP2019523637A (ja) 2019-08-29
MX2024002398A (es) 2024-04-03
EP3454832A1 (en) 2019-03-20
AU2017263237A1 (en) 2018-11-22
PH12018502361B1 (en) 2024-03-27
MA44986A (fr) 2019-03-20
CA3022865A1 (en) 2017-11-16
US20170327560A1 (en) 2017-11-16
JP2022061984A (ja) 2022-04-19
IL262652B1 (en) 2023-06-01
NZ787709A (en) 2025-10-31
JP2024102147A (ja) 2024-07-30
JP7481319B2 (ja) 2024-05-10
SG10201912739XA (en) 2020-02-27
TW202446785A (zh) 2024-12-01
US10336812B2 (en) 2019-07-02
MY191030A (en) 2022-05-29
CO2018012096A2 (es) 2018-11-22
IL302720B1 (en) 2025-03-01
CR20180532A (es) 2019-03-04
IL318871A (en) 2025-04-01
AU2021218103B2 (en) 2023-08-17
TW201803892A (zh) 2018-02-01
AU2023266233B2 (en) 2025-10-30
ECSP18083561A (es) 2018-11-30
IL262652B2 (en) 2023-10-01
KR102818007B1 (ko) 2025-06-12
MX2018013784A (es) 2019-03-28
AU2017263237B2 (en) 2021-05-20
EP3454832A4 (en) 2019-12-18
CN109451726A (zh) 2019-03-08
WO2017196647A1 (en) 2017-11-16
BR112018072946A2 (pt) 2019-02-19
KR20190003746A (ko) 2019-01-09
NZ748307A (en) 2025-10-31
US20230119382A1 (en) 2023-04-20
IL302720B2 (en) 2025-07-01
NI201800121A (es) 2019-02-18
DOP2018000245A (es) 2019-07-15
TW202225183A (zh) 2022-07-01
IL262652A (en) 2018-12-31
US20190292241A1 (en) 2019-09-26
PE20190352A1 (es) 2019-03-07
KR20230169417A (ko) 2023-12-15
JP7022879B2 (ja) 2022-02-21
PE20240015A1 (es) 2024-01-04
IL302720A (en) 2023-07-01
SG11201809700YA (en) 2018-11-29
UA129532C2 (uk) 2025-05-28
PH12018502361A1 (en) 2019-09-23
ZA201808284B (en) 2021-10-27
CL2018003148A1 (es) 2018-12-28
TWI853223B (zh) 2024-08-21
TWI760333B (zh) 2022-04-11
CR20230026A (es) 2023-03-13
US11208464B2 (en) 2021-12-28
SV2018005781A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
AR125392A2 (es) Métodos y composiciones para la expresión génica en plantas
AR114339A1 (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
MX2020009824A (es) Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
MX388739B (es) Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
MX2024015050A (es) L-asparaginasa modificada
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
AR093626A1 (es) Proteinas de fusion de enzima lisosomal y usos de las mismas
MX2017010880A (es) Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario.
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
CL2019003404A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407)
EA201892554A1 (ru) Мутант cd200 и его применения
AR057884A1 (es) Plantas con caracteristicas de crecimiento mejoradas y un metodo para desarrollarlas
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
NZ744289A (en) Composition containing amino acids
PE20190967A1 (es) Aislados modificados de streptomyces fungicidicus y su uso
UY38862A (es) Gonadotrofina coriónica recombinante, procedimiento para su preparación, composiciones farmacéuticas y usos de la misma.
PE20242117A1 (es) Acido nucleico optimizado por codones que codifica la proteina del factor de coagulacion ix, y su uso
AR117019A1 (es) Conjugados de interleuquina 10 y usos de los mismos
AR104231A1 (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer